Connect with us

Hi, what are you looking for?

Saturday, Dec 10, 2022
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.

The weed wire

MediPharm partners with Hybrid Pharm to offer same-day registration and delivery

On-site dispensary should be an industry norm, says MediPharm

MediPharm Labs completes fist topical shipment
MediPharm founders Keith Sachan

Medical cannabis patients in Ontario will soon be able to register for and have MediPharm Labs, Corp. (TSX: LABS and OTCQX: MEDIF) products delivered within the same day.

The Canadian extractor revealed the partnership with pharmaceutical company Hybrid Pharm, Inc. on Wednesday. Hybrid Pharm offers same-day registration and delivery. Its team of pharmacists also do drugs interaction checks and continuous care monitoring, MediPharm said in a statement.

“Medical cannabis users value the brand-name, pharma-quality products that MediPharm Labs provides through our GMP-certified Canadian production facility, but they also crave the touch that only pharmacists and their staff can deliver and that’s what patients receive at Hybrid Pharm,” CEO Pat McCutcheon said in the statement.

“We believe Hybrid Pharm’s approach to patient care aligns perfectly with our own philosophy and we are delighted to be chosen as a key supplier.”

Read more: MediPharm watches revenues fall 65 per cent

Hybrid Pharm is unique because it offers patients full in-store consultations, MediPharm says. The pharmacy’s approach to dispensing medical cannabis in-store, instead of the industry norm of mail orders, will hopefully become standard across Canada, the company added.

MediPharm was an attractive business partner because of its consistent quality, Hybrid Pharm CEO Rahim Dhalla said.

“As a full-service pharmacy dedicated to patient safety, we have very deliberately chosen to carry only trusted cannabis products that we can recommend with confidence and that’s exactly why we sought out MediPharm Labs as a supplier,” Dhalla said.

Read more: MediPharm blames slow cannabis 2.0 rollout for Q4 revenue drop

“Not only do they meet all of the qualifications we look for including GMP-certified production processes, their state-of-the-art facility is right here in Ontario which means reliable supply of branded formulations for our rapidly growing patient base,” he added.

MediPharm’s stock dipped a fraction of a cent on Thursday to $1.10 per share. Like most of the cannabis industry, the extractor’s stock has been slowly declining since the summer of 2019.

Top image of MediPharm founders Keith Strachan (left) and Pat McCutcheon (right). Image via MediPharm


Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like


The company will sell its cultivars Khiron Gelato 19/1 and Khiron Caramel 5/7 in the mountainous region


Pathway's Medical Cannabis Management System (MCMS) will be implemented this November


The deal will help Flora establish a foothold in the German medical cannabis market


Panaxia will manage manufacturing with Neuraxpharm responsible for marketing and distribution